Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

PRO.MED.CS Praha

PRO.MED.CS Praha a.s. is a Czech pharmaceutical Company located in Prague specialising in the manufacture of solid medicinal forms – tablets, film coated tablets and capsules. Our medicinal portfolio is primarily aimed at the cardiovascular, gastrointestinal and musculoskeletal areas and pain. We also provide medicines for mental disorders, bacterial and viral diseases. In addition to prescription medicines we produce over the counter medicines and trace elements too.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

Company Details

PRO.MED.CS Praha
Telcska 1, Prague, 140 00, Czech Republic
+420 241 013 111
Contact PRO.MED.CS Praha
Website

 Latest Content from PMHub 

UX: Designing Human Experiences

White Papers and Resources | April 24, 2014 | Havas Lynx

Applying science to the creative process to improve lives

08 UX: Pushing the right buttons

White Papers and Resources | March 31, 2014 | Havas Lynx

Unlocking better outcomes in healthcare with UX

UX: Pushing the right buttons

White Papers and Resources | March 31, 2014 | Havas Lynx

Unlocking better outcomes in healthcare with UX

07 Good Pharma

White Papers and Resources | January 3, 2014 | Havas Lynx

Better for patients, better for business

06 Our Opportunity to Rethink the Health Experience

White Papers and Resources | January 3, 2014 | Havas Lynx

Our point of view

05 Social Media: A Health Hazard?

White Papers and Resources | January 3, 2014 | Havas Lynx

The case to embrace going social

Creating a Lifeline to the New Digital User

White Papers and Resources | January 3, 2014 | Havas Lynx

Today, we’re focussed on getting to know our new target: she’s online, mobile, and connected to a large network of friends, information, and marketers who help her make decisions about...

Warehousing of HCV patients reaches new high

White Papers and Resources | December 19, 2013 | Inizio

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

White Papers and Resources | December 19, 2013 | Inizio

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Removing the Roadblocks to Effective Patient Treatment

White Papers and Resources | November 22, 2013 | Inizio

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...